HPRT1 and chronic myelogenous leukemia, BCR-ABL1 positive: The thiopurine drug 6-mercaptopurine (6-MP), which has been used for acute lymphoblastic leukemia (ALL) and chronic myeloid leukemia (CML) treatment, competes with HPRT1 substrates and thereby inhibits HPRT1 activity30.